6 studies found for:    ((pazopanib AND GIST)OR Nct01391611 OR Nct01392352 OR NCT01339871 OR NCT01485042) | Open Studies
Show Display Options
Rank Status Study
1 Unknown  Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Pazopanib
2 Recruiting HYPAZ: Hypertension Induced by Pazopanib
Conditions: Renal Cell Carcinoma;   Soft Tissue Sarcoma;   Glioblastoma;   Ovarian Cancer;   Cervical Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Pancreatic Cancer;   Melanoma;   Gastrointestinal Cancer
Intervention: Drug: Pazopanib
3 Recruiting Phase I Study of Pazopanib and Vorinostat
Condition: Advanced Cancer
Interventions: Drug: Pazopanib;   Drug: Vorinostat
4 Recruiting Caphosol in Oral Mucositis Due to Targeted Therapy
Conditions: Oral Mucositis;   Renal Cell Carcinoma;   Hepatocellular Carcinoma;   Gastrointestinal Stromal Tumors
Interventions: Other: supersaturated calcium-phosphate rinse;   Other: sodium chloride 0.9 %
5 Recruiting A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Interventions: Drug: Pazopanib;   Drug: Doxorubicin
6 Recruiting A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Conditions: Liposarcoma;   Osteogenic Sarcoma;   Ewing/Ewing-like Sarcoma
Interventions: Drug: Regorafenib;   Drug: Placebo

Indicates status has not been verified in more than two years